Fmr LLC Buys 170,810 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

FMR LLC grew its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 2.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,363,530 shares of the company's stock after purchasing an additional 170,810 shares during the period. FMR LLC owned about 2.98% of Recursion Pharmaceuticals worth $55,116,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Allspring Global Investments Holdings LLC bought a new position in shares of Recursion Pharmaceuticals during the 3rd quarter valued at $25,000. Farther Finance Advisors LLC raised its holdings in Recursion Pharmaceuticals by 176.9% during the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company's stock valued at $42,000 after buying an additional 4,091 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Recursion Pharmaceuticals by 1,588.4% in the second quarter. GAMMA Investing LLC now owns 6,416 shares of the company's stock worth $48,000 after buying an additional 6,036 shares during the last quarter. KBC Group NV boosted its stake in shares of Recursion Pharmaceuticals by 79.9% during the 3rd quarter. KBC Group NV now owns 7,602 shares of the company's stock worth $50,000 after acquiring an additional 3,377 shares in the last quarter. Finally, Amalgamated Bank increased its holdings in shares of Recursion Pharmaceuticals by 52.4% during the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company's stock valued at $54,000 after acquiring an additional 2,459 shares during the last quarter. 89.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have commented on RXRX shares. Jefferies Financial Group lowered their price target on Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating on the stock in a report on Tuesday, September 3rd. Leerink Partners dropped their target price on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating on the stock in a report on Tuesday, September 3rd. Finally, Needham & Company LLC restated a "buy" rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Wednesday, November 20th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $9.25.

Recursion Pharmaceuticals Stock Performance

NASDAQ RXRX traded up $1.42 during midday trading on Friday, hitting $8.01. The company had a trading volume of 30,761,670 shares, compared to its average volume of 10,777,311. The firm has a fifty day simple moving average of $6.61 and a two-hundred day simple moving average of $7.32. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $5.60 and a fifty-two week high of $15.74. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock has a market cap of $2.30 billion, a price-to-earnings ratio of -5.24 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm had revenue of $26.08 million during the quarter, compared to analyst estimates of $12.62 million. During the same period last year, the company earned ($0.43) EPS. The company's revenue was up 147.6% on a year-over-year basis. Equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Blake Borgeson sold 11,447 shares of the firm's stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $6.84, for a total transaction of $78,297.48. Following the completion of the sale, the director now directly owns 7,109,875 shares of the company's stock, valued at $48,631,545. This trade represents a 0.16 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Tina Marriott sold 6,000 shares of the business's stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $7.00, for a total value of $42,000.00. Following the completion of the transaction, the chief operating officer now directly owns 521,138 shares in the company, valued at approximately $3,647,966. This represents a 1.14 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 134,235 shares of company stock worth $895,538 over the last 90 days. Corporate insiders own 15.75% of the company's stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.